- METHOD FOR PRODUCING IMIDIC ACID COMPOUND
-
Disclosed is a method for producing "a salt or a complex comprising imidic acid and an organic base", characterized by reacting halogenated sulfuryl or halogenated phosphoryl with ammonia in the presence of an organic base. According to this method, a target imidic acid compound can be produced in a high yield while significantly suppressing the production of by-products. Further, by reacting the obtained imidic acid compound with an alkali metal hydroxide or an alkaline earth metal hydroxide, an imidic acid metal salt can be easily derived.
- -
-
Page/Page column 11-12
(2012/02/15)
-
- Compounds useful for treating AIDS
-
The present invention relates to compound (I) for use as an agent for preventing, inhibiting or treating AIDS. The present invention further relates to compounds of formula (I) wherein X is CR0 or N; R0, R1, R2, R3, R4, R7 and R8 independently represent a hydrogen atom, a halogen atom or a group chosen among a (C1-C5)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)fluoroalkyl group, a (C1-C5)alkoxy group, a (C1-C5)fluoroalkoxy group, a -CN group, a -COORa group, a -NO2 group, a -NRaRb group, a -NRa-SO2-NRaRb group, a -NRa-SO2-Ra group, a -NRa-C(=O)-Ra group, a -NRa-C(=O)-NRaRb group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group, a -O-P(=O)-(ORc)(ORd) group, a -O-CH2-COORc group and can further be a group chosen among: R5 represents a hydrogen atom, a (C1-C5)alkyl group or a (C3-C6)cycloalkyl group; R10 is a hydrogen atom or a chlorine atom, and R11 is a hydrogen atom or a (C1-C4)alkyl group or anyone of its pharmaceutically acceptable salts.
- -
-
-
- 2,3-oxidosqualene-lanosterol cyclase inhibitors
-
The present invention relates to aminocyclohexanol derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.
- -
-
-
- Synthesis of 1,3,5-trisubstituted pyrazoles
-
A novel process for making 1,3,5-trisubstituted pyrazoles of the type shown below from appropriate phenyl hydrazines is described. These compounds are useful as factor Xa inhibitors.
- -
-
-
- META-SUBSTITUTED PHENYLENE SULPHONAMIDE DERIVATIVES
-
The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the alphavbeta3 integrin.
- -
-
-
- BENZIMIDAZOLE DERIVATIVES
-
The present invention provides novel benzimidazole derivatives of the following formula (I) and salts thereof: wherein R1 represents a lower alkyl group or a lower alkyloxy-lower alkyl group: R2 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an aryl group, and such; R3 represents a lower alkyl group, a lower alkenyl group, an aryl group, a lower alkylaryl group, an aryl-lower alkenyl group, a halothienyl group, a lower alkylamino group, or an aryl-lower alkylamino group; A represents a benzene ring, a naphthalene ring, or a pyridine ring; and X represents a halogen atom. The derivatives and their salts have blood sugar level-depressing activity or PDE5-inhibiting activity, and are useful as pharmaceutical preparations.
- -
-
-
- METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS
-
Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN-γ in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon-γ inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a factor that regulates production of IFN-γ in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.
- -
-
-
- Sulfonamide substituted aspartic acid interleukin-1 beta converting enzyme inhibitors
-
PCT No. PCT/US97/18406 Sec. 371 Date Apr. 9, 1999 Sec. 102(e) Date Apr. 9, 1999 PCT Filed Oct. 9, 1997 PCT Pub. No. WO98/16504 PCT Pub. Date Apr. 23, 1998The present invention relates to compounds that are inhibitors of interleukin-1 beta converting enzyme that have the Formula I, II, or III. This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 beta converting enzyme.
- -
-
-
- Meta-substituted phenylene sulphonamide derivatives
-
The present invention relates to a class of compounds represented by the Formula I STR1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αv β3 integrin.
- -
-
-
- Cyclised analogues of fatty acid metabolites
-
A compound selected from those of formula (I): STR1 wherein A, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the description. This compound or its physiologically tolerable salts may be used therapeutically as platelet anti-aggregation agent.
- -
-
-
- 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS
-
The present invention relates to compounds of formula I which are 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl[b]pyran-2-ones useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus. STR1 Wherein R 10 and R 20 taken together are: STR2
- -
-
-
- A new organosilylpolyphosphoric reagent, its preparation and application to the process of synthesis of 3-carboxyquinolones or azaquinolones and their salts
-
A process for the preparation of new organosilylpoly-phosphates from the reaction of phosphorus pentoxide with a siloxane or alkyloxysilane to obtain, in solution, reagents the composition of which is [P2O5]N[SILANE], where 1 N 10 where N is a function of temperatu-re, reaction time and solvent, being applied to the modulation of cyclization reaction of N-susbtituted aminomethylenemalonates leading to quinolones or azaqui-nolones. The N-substituted aminomethylenemalonates are prepared by the reaction of anilines with dialkyl trimethylsilyloxy-methylene-malonates.
- -
-
-
- Process of preparing azoalkane mixture containing at least one unsymmetrical azoalkane
-
Mixtures of azoalkanes of varying thermal stabilities at least one of which is an unsymmetrical azoalkane (R--N=N--R'), are prepared by reacting 4 equivalents of a mixture of two or more primary alkyl, cycloalkyl or aralkylamines with 1 equivalent of sulfuryl chloride in an inert solvent and oxidizing the resulting mixture of sulfamide products with basic bleach. The unsymmetrical azoalkanes can be separated from the symmetrical azoalkanes by a variety of conventional techniques. The azoalkane mixtures are excellent polymerization initiators for vinyl monomers and curing agents for unsaturated polyester resins.
- -
-
-
- Dioxazine reactive dyestuffs
-
The invention relates to new dioxazine reactive dyestuffs of the formula STR1 a process for their preparation and their use in dyeing and printing fibre materials which contain hydroxyl groups or amide groups. In formula (I): D denotes a radical of the dioxazine system of the formula STR2 the radicals Y, Z, A, X1 and X2 as well as m and n having the meaning indicated in the text of the application. The invention further relates to a process for the preparation of these new dioxazine reactive dyestuffs as well as their use in dyeing and printing fibre materials which contain hydroxyl groups or amide groups.
- -
-
-
- Kinetic study of the hydrolysis of sulfamido, p-toluenesulfonamido, and p-nitrobenzenesulfonamido complexes of pentaamminecobalt(III) in acidic aqueous solution
-
The pentaamminecobalt(III) complexes of NH2SO2NH-, p-CH3C6H4SO2NH-, and p-NO2C6H4SO2NH- have been prepared and c
- Laird, Janet L.,Jordan, Robert B.
-
p. 855 - 858
(2008/10/08)
-
